The PRECiSE 2 trial of certolizumab pegol , a new PEGylated anti- P01375 agent , in the treatment of Crohn 's disease : An interview with David A Schwartz , 13 June 2007 . DB08904 ( CDP 870 ) is a new anti-tumor necrosis factor ( P01375 ) therapy currently in development for the treatment of Crohn 's disease , rheumatoid arthritis , and psoriasis . DB08904 is the first PEGylated biologic anti- P01375 agent and has a high binding affinity for P01375 . Dr. Schwartz was an investigator of the PRECiSE ( PEGylated Antibody Fragment Evaluation in Crohn 's Disease Safety and Efficacy ) 2 trial of certolizumab pegol in patients with Crohn 's disease .